Verrica Pharmaceuticals Inc.
VRCAVerrica Pharmaceuticals Inc. in brief
Verrica Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in West Chester, Pennsylvania, USA. It was founded in 2013. Its market value was $76 M on 21 September 2026, which makes it the 19,728th largest listed company in the world and the 3,666th largest in the USA on this site. In the year to December 2025 it had sales of $36 M and a net loss of $18 M. It employs about 76 people and Jayson Rieger is its chief executive. Its largest product and service lines by sales in 2025 were License and collaboration revenue (57%) and License and Collaboration Revenue, Commercial Supply and Development (6%). Its shares trade under the symbol VRCA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Verrica Pharmaceuticals Inc.
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are currently developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Our second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, or BCC.
From the company's annual report filed with the US SEC: read the report
Verrica Pharmaceuticals Inc. timeline
- 2013
- 🏁· approximateFounded
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 15 June 2018; shares registered for exchange trading on 13 June 2018.
- 2025
- 💰Record revenue of $36 millionFY2025, the highest of the 5 years on record.
Events of Verrica Pharmaceuticals Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,647 (Jan 2020) · #2,962 (Jan 2021) · #3,641 (Jan 2022) · #4,263 (Dec 2022) · #3,443 (Jul 2023) · #2,970 (Jan 2024) · #1,984 (Mar 2026) · #3,513 (Aug 2026) · #3,646 (Sep 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.5×
- Price / book
- 3.1×
- Free cash flow yield
- -23.1%
- Net margin (TTM)
- -102.8%
- Operating margin
- -34.2%
- Return on equity
- -126.0%
- Liabilities / assets
- 47.5%
- Net debt
- $-30M
- Revenue growth
- +370.0%
- R&D / revenue
- 24.9%
- Revenue per employee
- $468 K
- Profit per employee
- $-235 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $36M | +370.0% | $-12M | $-18M | -50.3% |
| Dec 2024 | $8M | +47.9% | $-66M | $-77M | -1011.6% |
| Dec 2023 | $5M | -43.3% | $-66M | $-67M | -1308.6% |
| Dec 2022 | $9M | -24.8% | $-21M | $-24M | -271.2% |
| Dec 2021 | $12M | — | $-31M | $-35M | -292.3% |
| Dec 2020 | — | — | $-40M | $-43M | — |
| Dec 2019 | — | — | $-30M | $-28M | — |
| Dec 2018 | — | — | $-22M | $-21M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-18M | $0M | $-18M | $-1.68 | — |
| Dec 2024 | $-61M | $0M | $-61M | $-14.78 | — |
| Dec 2023 | $-39M | $0M | $-39M | $-1.48 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-0.72 | — |
| Dec 2021 | $-28M | $1M | $-28M | $-1.30 | — |
| Dec 2020 | $-30M | $1M | $-32M | $-1.71 | — |
| Dec 2019 | $-27M | $1M | $-28M | $-1.13 | — |
| Dec 2018 | $-18M | $1M | $-19M | $-1.41 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $7M (-51.8% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 9, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 20, 2026DEF 14AProxy statement
- Mar 11, 202610-KAnnual report · period to Dec 2025
- Mar 11, 20268-KCurrent reportResults of operations
- Dec 30, 20258-KCurrent reportDirectors or officers changed
- Nov 24, 20258-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Nov 14, 202510-QQuarterly report · period to Sep 2025
Official filings of Verrica Pharmaceuticals Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $36 M
- Operating income
- $-12 M
- Net income
- $-18 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $47 M
- Total liabilities
- $22 M
- Total equity
- $25 M
As of December-2025
Top 39 institutional investors in Verrica Pharmaceuticals Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Caligan Partners LP | 923,910 | 0 (0.00%) | 5.38% | $4 M | Nov 16, 2026 |
| 2 | Cannell Capital LLC | 693,552 | -90,371 (-11.53%) | 4.04% | $3 M | Nov 16, 2026 |
| 3 | Affinity Asset Advisors, LLC | 688,654 | -18,684 (-2.64%) | 4.01% | $3 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 351,910 | +72,600 (+25.99%) | 2.05% | $2 M | Nov 13, 2026 |
| 5 | Boothbay Fund Management, LLC | 280,734 | 0 (0.00%) | 1.63% | $1 M | Nov 16, 2026 |
| 6 | Mariner, LLC | 214,030 | +6,800 (+3.28%) | 1.25% | $1 M | Nov 12, 2026 |
| 7 | Armistice Capital, LLC | 206,472 | -219,832 (-51.57%) | 1.20% | $1 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 128,298 | -9,862 (-7.14%) | 0.75% | $1 M | Nov 6, 2026 |
| 9 | BlackRock, Inc. | 72,098 | -2,246 (-3.02%) | 0.42% | $0 M | Nov 13, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 53,505 | -16,668 (-23.75%) | 0.31% | $0 M | Nov 13, 2026 |
| 11 | Citadel Advisors LLC | 39,002 | New | 0.23% | $0 M | Nov 16, 2026 |
| 12 | Verdad Advisers, LP | 35,414 | +12,345 (+53.51%) | 0.21% | $0 M | Nov 16, 2026 |
| 13 | Renaissance Technologies LLC | 31,884 | +10,115 (+46.47%) | 0.19% | $0 M | Nov 12, 2026 |
| 14 | Northern Trust Corp | 30,806 | +3,810 (+14.11%) | 0.18% | $0 M | Nov 16, 2026 |
| 15 | State Street Corp | 28,916 | 0 (0.00%) | 0.17% | $0 M | Nov 12, 2026 |
| 16 | XTX Topco Ltd | 28,686 | +14,963 (+109.04%) | 0.17% | $0 M | Nov 16, 2026 |
| 17 | Fifth Third Bancorp | 28,000 | +14,000 (+100.00%) | 0.16% | $0 M | Nov 5, 2026 |
| 18 | Two Sigma Investments, LP | 24,268 | -16,557 (-40.56%) | 0.14% | $0 M | Nov 16, 2026 |
| 19 | DAFNA Capital Management LLC | 23,750 | 0 (0.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 20 | Legacy Trust | 16,584 | 0 (0.00%) | 0.10% | $0 M | Nov 6, 2026 |
| 21 | Jane Street Group, LLC | 16,297 | -7,357 (-31.10%) | 0.09% | $0 M | Nov 12, 2026 |
| 22 | Beck Mack & Oliver LLC | 12,000 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 23 | Morgan Stanley | 6,132 | +2,931 (+91.57%) | 0.04% | $0 M | Nov 13, 2026 |
| 24 | Royal Bank Of Canada | 2,074 | +1,310 (+171.47%) | 0.01% | $0 M | Nov 16, 2026 |
| 25 | Capital Analysts, LLC | 1,500 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Show all 39: investors 26 to 39
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 1,448 | -4,623 (-76.15%) | 0.01% | $0 M | Nov 10, 2026 |
| 27 | Vanguard Global Advisers, LLC | 862 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 608 | -6 (-0.98%) | 0.00% | $0 M | Nov 16, 2026 |
| 29 | Salomon & Ludwin, LLC | 290 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 30 | New England Capital Financial Advisors LLC | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 31 | Fortitude Family Office, LLC | 127 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 32 | BNP Paribas Financial Markets | 101 | -9 (-8.18%) | 0.00% | $0 M | Nov 12, 2026 |
| 33 | Jpmorgan Chase & Co | 47 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Caitong International Asset Management Co., Ltd | 28 | New | 0.00% | $0 M | Oct 29, 2026 |
| 35 | Jones Financial Companies Lllp | 26 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 36 | Valley National Advisers Inc | 25 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 37 | PNC Financial Services Group, Inc. | 20 | -82 (-80.39%) | 0.00% | $0 M | Nov 6, 2026 |
| 38 | FMR LLC | 10 | New | 0.00% | $0 M | Nov 10, 2026 |
| 39 | Barclays PLC | 4 | -60 (-93.75%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Verrica Pharmaceuticals Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 143,141 | $1 M | 0.83% | <0.01% | +171% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 135,465 | $1 M | 0.79% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 61,808 | $0 M | 0.36% | <0.01% | +119% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 33,630 | $0 M | 0.20% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 20,514 | $0 M | 0.12% | <0.01% | +84% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 17,055 | $0 M | 0.10% | <0.01% | +80% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 10,929 | $0 M | 0.06% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 7,373 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,195 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 1,982 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 2,088 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 1,645 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 800 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 481 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 262 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 90 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 51 | $0 M | <0.01% | <0.01% | +22% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 17 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Verrica Pharmaceuticals Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John J. KirbyInterim CFO | Buy | +5,000 | $4.930 | $25 K | 23,962 | Form 4 |
| filed | Noah L. RosenbergCMO | Buy | +2,030 | $4.920 | $10 K | 8,587 | Form 4 |
| filed | Noah L. RosenbergCMO | Buy | +4,200 | $4.910 | $21 K | 6,557 | Form 4 |
| filed | David ZawitzChief Operating Officer | Buy | +6,000 | $4.980 | $30 K | 27,000 | Form 4 |
| filed | Jayson RiegerCEO and President, Director | Buy | +5,000 | $4.910 | $25 K | 207,593 | Form 4 |
| filed | Jayson RiegerCEO and President, Director | Buy | +20,000 | $5.060 | $101 K | 202,593 | Form 4 |
| filed | John J. KirbyInterim CFO | Grant or award | +10,000 | — | — | 18,962 | Form 4 |
| filed | John J. KirbyInterim CFO | Buy | +3,536 | $4.240 | $15 K | 8,962 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Verrica Pharmaceuticals Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1.714-for-1 split
Trading halts
- 2025-07-24 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 4 shares at $4.45
- : 533 shares at $4.65
- : 175 shares at $4.91
- : 46 shares at $5.26
- : 2,156 shares at $5.39
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Verrica Pharmaceuticals Inc. scorecard#
Passes 10 of the 21 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Sep 21, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median2.5×Price to sales 2.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-23.1%Free cash flow is -23.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year370.0%Revenue up 370.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years58.0%58.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median58.0%58.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.68 vs -14.78Diluted EPS -1.68 in fiscal 2025 against -14.78 the year before (report's currency).
- ✓Net income higher than five years earlier-$18 M-$18 M in fiscal 2025 against -$43 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 5
- ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-34.2%-34.2% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-240.5%-240.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-34.2%-34.2% in fiscal 2025 against -235.9% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.59 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $30 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-7.04Z-score -7.04 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year105.6%Diluted shares up 105.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Verrica Pharmaceuticals Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -34.2% | -60.5% | |
| Net margin | -50.3% | -68.9% | |
| Return on equity | -240.5% | -61.0% | |
| Revenue growth, 3 years a year | 58.0% | 12.9% | |
| Revenue growth | 370.0% | 15.8% | |
| Debt to equity | 0.00× | 0.26× |
5of 8on the Piotroski tests of financial strength
- Net loss of $18 million, the 9th loss-making year in a row.
- Free cash flow was negative: -$18 million.
- The share count rose 105.6% in the year.
- More cash than debt: net cash of $30 million.
Verrica Pharmaceuticals Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 36+370%100% | 7.6+47.7%100% | 5.1−43.3%100% | 9.0−24.7%100% | 12—100% | — | — | — | — | |
| Cost of revenue | — | 2.6+420%34.4% | 0.5—9.8% | — | — | — | — | — | — | |
| Research and development | 8.9−25.2%24.9% | 12−41.7%156% | 20+66.4%396% | 12−23.4%135% | 16+1.6%133% | 16+1.5%— | 15+20.3%— | 13+244%— | 3.7—— | |
| Selling, general and administrative | 35−40.1%99.0% | 59+24.3%777% | 47+172%923% | 17—193% | — | — | — | — | — | |
| General and administrative | — | — | — | 17−35.5%193% | 27+10.1%225% | 25+67.4%— | 15+61.8%— | 9.1+1145%— | 0.7—— | |
| Operating expenses | 48−35.0%134% | 73+3.7%971% | 71+134%1383% | 30−29.3%336% | 43+6.8%358% | 40+33.6%— | 30+37.5%— | 22+391%— | 4.5—— | |
| Operating income | −12—−34.2% | −66—−871% | −66—−1283% | −21—−236% | −31—−258% | −40—— | −30—— | −22—— | −4.5—— | |
| Interest and finance income | 0.9−34.4%2.6% | 1.4−48.3%18.7% | 2.7+476%53.5% | 0.5+287%5.3% | 0.1−76.4%1.0% | 0.5−72.2%— | 1.9+52.5%— | 1.2—— | — | |
| Interest expense and finance costs | 7.7−17.7%21.8% | 9.4+138%124% | 4.0+82.4%77.3% | 2.2−49.4%24.0% | 4.3+41.6%35.8% | 3.0r3.0—— | — | — | — | |
| Other non-operating income (expense) | −5.7—−16.0% | −11—−141% | −1.2—−24.1% | −3.2—−35.3% | −4.2—−34.8% | −2.5−234%— | 1.9+52.3%— | 1.2—— | −0.0—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Net income including minority interests | — | −77—−1012% | −67—−1307% | −24—−271% | −35—−292% | −43—— | −28—— | −21—— | — | |
| Net income attributable to shareholders | −18—−50.3% | −77—−1012% | −67—−1307% | −24—−271% | −35—−292% | −43—— | −28—— | −21—— | −4.5—— | |
| Earnings per share, basic | -1.68—— | -14.78r-1.48—— | -1.48—— | -0.72—— | -1.30—— | -1.71—— | -1.13—— | -1.41—— | -1.56—— | |
| Earnings per share, diluted | -1.68—— | -14.78r-1.48—— | -1.48—— | -0.72—— | -1.30—— | -1.71—— | -1.13—— | -1.41—— | -1.56—— | |
| Shares, weighted average (basic) | 11+106%— | 5.2r52−88.6%— | 45+32.7%— | 34+26.3%— | 27—— | — | — | — | — | |
| Shares, weighted average (diluted) | 11+106%— | 5.2r52−88.6%— | 45+32.7%— | 34+26.3%— | 27+8.2%— | 25+0.4%— | 25+69.8%— | 15+414%— | 2.9—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 30−34.9%64.0% | 46−33.4%85.6% | 70+103%85.2% | 34+118%76.6% | 16+47.4%19.7% | 11+15.6%14.4% | 9.2−10.0%13.5% | 10+18.6%11.2% | 8.7—95.4% | |
| Short-term investments | — | — | — | 0—0.0% | 0—0.0% | — | — | — | — | |
| Receivables | 5.3+10858%11.2% | 0.0−98.9%0.1% | 4.2—5.2% | 0—0.0% | — | — | — | — | — | |
| Inventory | 2.2−9.2%4.7% | 2.5+141%4.5% | 1.0—1.3% | 0—0.0% | — | — | — | — | — | |
| Other current assets | 2.8+21.3%5.9% | 2.3−9.2%4.3% | 2.5−41.6%3.1% | 4.4+9.6%9.7% | 4.0+82.3%5.0% | 2.2−26.5%2.9% | 3.0+121%4.3% | 1.3+220%1.5% | 0.4—4.6% | |
| Current assets | 43−16.9%90.3% | 51−34.0%94.5% | 78+98.2%95.0% | 39−47.4%87.5% | 74+9.9%92.8% | 68+4.1%91.2% | 65−28.7%95.0% | 91+904%99.2% | 9.1—100% | |
| Property, plant and equipment | 0.2−64.5%0.4% | 0.6−44.0%1.1% | 1.1−72.9%1.3% | 3.9−0.2%8.7% | 3.9+25.5%4.9% | 3.1+48.4%4.2% | 2.1+720%3.1% | 0.3—0.3% | — | |
| Right-of-use (leased) assets | 0.5−35.4%1.1% | 0.8−27.8%1.5% | 1.2−19.8%1.4% | 1.4−10.3%3.2% | 1.6−12.4%2.0% | 1.8+1554%2.5% | 0.1—0.2% | — | — | |
| Total assets | 47−12.9%100% | 54−33.7%100% | 82+82.5%100% | 45−44.2%100% | 80+8.1%100% | 74+8.4%100% | 68−25.6%100% | 92+912%100% | 9.1—100% | |
| Accounts payable | 2.1+9.3%4.4% | 1.9−23.1%3.5% | 2.5+386%3.0% | 0.5−40.0%1.1% | 0.8+143%1.1% | 0.3−70.6%0.5% | 1.2+28.5%1.7% | 0.9+503%1.0% | 0.2—1.7% | |
| Debt due within a year | 0−100%0.0% | 13—23.9% | 0—0.0% | — | — | 35—47.6% | — | — | — | |
| Current liabilities | 16−43.3%34.9% | 29+70.4%53.6% | 17+392%20.9% | 3.5−92.5%7.7% | 46+16.7%57.5% | 39+1078%53.2% | 3.4+35.3%4.9% | 2.5+302%2.7% | 0.6—6.8% | |
| Lease liabilities (non-current) | 0.2−58.5%0.5% | 0.6−35.9%1.1% | 0.9−26.0%1.1% | 1.2−15.2%2.7% | 1.4−14.4%1.8% | 1.7+2819%2.3% | 0.1—0.1% | — | — | |
| Total liabilities | 22−65.0%47.5% | 64+3.5%118% | 62+1219%75.8% | 4.7−90.1%10.5% | 48+15.4%59.3% | 41+1108%55.5% | 3.4+37.6%5.0% | 2.5+302%2.7% | 0.6—6.8% | |
| Retained earnings | −325—−689% | −307—−567% | −230—−282% | −163—−365% | −139—−173% | −104—−140% | −61—−89.4% | −33—−36.0% | −12—−137% | |
| Shareholders' equity | 25—52.5% | −9.9−150%−18.2% | 20−50.6%24.2% | 40+22.8%89.5% | 33−1.2%40.7% | 33−49.3%44.5% | 65−27.3%95.0% | 89—97.3% | −7.0—−77.5% | |
| Total liabilities and equity | 47−12.9%100% | 54−33.7%100% | 82+82.5%100% | 45−44.2%100% | 80+8.1%100% | 74+8.4%100% | 68−25.6%100% | 92+912%100% | 9.1—100% | |
| Shares outstanding | 17+87.2%— | 9.2r92−78.4%— | 42+3.2%— | 41+49.3%— | 28+8.2%— | 25−1.3%— | 26+0.3%— | 26+595%— | 3.7—— | |
| Cash-flow statement | ||||||||||
| Share-based compensation | 3.3−53.7%9.3% | 7.2−50.2%94.7% | 14+188%281% | 5.0−17.6%55.2% | 6.1−38.4%50.4% | 9.8+195%— | 3.3+48.1%— | 2.3+2645%— | 0.1—— | |
| Cash from operating activities | −18—−49.5% | −61—−805% | −39—−753% | −19—−206% | −28—−230% | −30—— | −27—— | −18—— | −4.6—— | |
| Capital expenditure | 0—0.0% | −0.0—−0.4% | −0.4—−7.1% | −0.3—−3.3% | −0.9—−7.4% | −1.5—— | −0.7—— | −0.8r−0.3—— | — | |
| Cash from investing activities | 0—0.0% | −0.0—−0.3% | −0.4−101%−7.1% | 54—598% | −1.0—−8.3% | −3.6−114%— | 26—— | −80—— | — | |
| Shares issued | — | — | — | 27−4.3%298% | 28—234% | — | — | — | — | |
| Cash from financing activities | 1.4−96.2%4.1% | 38−49.2%499% | 74—1448% | −17−150%−187% | 34−4.5%280% | 35+8229%— | 0.4−99.6%— | 99+681%— | 13—— | |
| Change in cash | −16—−45.5% | −23−166%−307% | 35+90.5%688% | 19+266%205% | 5.1+251%42.2% | 1.4—— | −1.0−164%— | 1.6−80.2%— | 8.1—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 23−25.7%100% | 6.9−51.8%100% | 5.9−53.8%100% | 5.0+46.1%100% | 5.1*+1380%100% | 14—100% | 13+145%100% | 3.4−10.1%100% | 0.3*−82.7%100% | −1.8—— | 5.2—100% | 3.8—100% | 2.0*—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 0.70.0%20.4% | 0.8*+300%233% | 0.4—— | 0.7—13.5% | 0.7—18.3% | 0.2*—10.1% | |
| Research and development | 20+166%87.3% | 7.6+244%110% | 6.0+227%103% | 3.9+69.0%76.8% | 2.5*+116%49.5% | 2.2−8.3%15.4% | 1.8−44.4%14.5% | 2.3−53.8%66.4% | 1.2r1.2*−78.0%340% | 2.4—— | 3.3—64.1% | 4.9—129% | 5.3*—268% | |
| Selling, general and administrative | 39+4.9%170% | 10+10.1%150% | 10+16.9%177% | 10.0+12.9%199% | 8.1*−17.8%159% | 9.4−41.5%65.6% | 8.9−46.4%69.7% | 8.8−45.8%257% | 9.9r9.9*−41.9%2872% | 16—— | 17—319% | 16—427% | 17*—855% | |
| Operating expenses | 65+37.7%284% | 19+50.0%276% | 19+69.4%323% | 15+27.4%293% | 12*+4.5%241% | 13−32.8%88.7% | 11−45.1%88.1% | 12−48.4%336% | 12*−53.2%3417% | 19—— | 20—394% | 22—586% | 25*—1264% | |
| Operating income | −42—−184% | −12−848%−176% | −13−967%−223% | −9.7—−193% | −7.2*—−141% | 1.6—11.3% | 1.5—11.9% | −8.1—−236% | −11*—−3317% | −21—— | −15—−294% | −19—−486% | −23*—−1164% | |
| Interest and finance income | 0.6−39.5%2.5% | 0.0−71.7%0.7% | 0.1−51.3%1.9% | 0.2−40.4%4.0% | 0.2*0.0%4.0% | 0.2−28.1%1.1% | 0.2−42.0%1.8% | 0.3−43.6%9.8% | 0.2*−74.1%59.6% | 0.2—— | 0.4—7.6% | 0.6—15.6% | 0.8*—39.8% | |
| Interest expense and finance costs | 1.9−78.1%8.4% | 0.3−86.4%4.1% | 0.2−92.3%2.8% | 0.2−92.7%3.2% | 1.3*−44.1%25.8% | 2.1−11.9%14.6% | 2.1−10.0%16.8% | 2.2−5.0%64.1% | 2.3*+1.9%683% | 2.4—— | 2.4—45.7% | 2.3—60.6% | 2.3*—116% | |
| Other non-operating income (expense) | −1.1—−5.0% | −0.2—−3.5% | −0.1—−1.0% | 0.0—0.7% | −0.9*—−17.3% | −1.9—−13.3% | −1.3—−10.3% | −1.6—−46.9% | −4.8*—−1393% | −2.2—— | −2.0—−38.2% | −1.7—−45.3% | −1.5*—−74.3% | |
| Net income including minority interests | — | — | — | — | — | — | 0.2*—1.6% | −9.7—−283% | −16*—−4710% | −23*—— | −17*—−332% | −20—−531% | −25*—−1238% | |
| Net income attributable to shareholders | −43—−189% | −12—−179% | −13−6548%−224% | −9.7—−193% | −8.1*—−159% | −0.3—−1.9% | 0.2—1.6% | −9.7—−283% | −16*—−4710% | −23—— | −17—−332% | −20—−531% | −25*—−1238% | |
| Earnings per share, basic | — | -0.58—— | -0.62−3200%— | -0.45—— | — | -0.03—— | 0.02—— | -1.03r-0.10—— | — | -4.88r-0.49—— | -3.70r-0.37—— | -0.44—— | — | |
| Earnings per share, diluted | — | -0.58—— | -0.62−3200%— | -0.45—— | — | -0.03—— | 0.02—— | -1.03r-0.10—— | — | -4.88r-0.49—— | -3.70r-0.37—— | -0.44—— | — | |
| Shares, weighted average (basic) | 21+124%— | 21+124%— | 21+125%— | 21+125%— | — | 9.5+103%— | 9.5+104%— | 9.5r95−79.6%— | — | 4.7r47—— | 4.7r47—— | 46—— | — | |
| Shares, weighted average (diluted) | 21+124%— | 21+124%— | 21+124%— | 21+125%— | — | 9.5+103%— | 9.5+104%— | 9.5r95−79.6%— | — | 4.7r47—— | 4.7r47—— | 46—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 14—36.1% | 14−31.8%36.1% | 11−27.3%31.1% | 21−30.4%53.1% | 30−34.9%64.0% | 21−8.1%51.6% | 15−51.8%39.4% | 30−39.5%70.2% | 46−33.4%85.6% | 23—69.7% | 32—61.4% | 49—73.8% | 70—85.2% | |
| Receivables | 11—28.2% | 11+59.5%28.2% | 11+19.0%30.4% | 7.7+37.8%19.9% | 5.3+10858%11.2% | 7.0—17.2% | 9.2−8.3%23.5% | 5.6−19.9%13.3% | 0.0−98.9%0.1% | 0—0.0% | 10—19.3% | 7.0—10.6% | 4.2—5.2% | |
| Inventory | 2.8—7.0% | 2.8+21.7%7.0% | 2.7+7.5%7.5% | 2.0−19.7%5.1% | 2.2−9.2%4.7% | 2.3−10.8%5.6% | 2.5−6.7%6.4% | 2.5−1.6%5.8% | 2.5+141%4.5% | 2.6—7.8% | 2.7—5.2% | 2.5—3.8% | 1.0—1.3% | |
| Other current assets | 3.7—9.4% | 3.7+4.0%9.4% | 2.6+75.5%7.3% | 2.4+34.0%6.1% | 2.8+21.3%5.9% | 3.6+40.1%8.8% | 1.5−39.7%3.8% | 1.8−24.6%4.2% | 2.3−9.2%4.3% | 2.6—7.8% | 2.5—4.8% | 2.3—3.5% | 2.5—3.1% | |
| Current assets | 36—91.3% | 36+0.3%91.3% | 33−11.3%90.6% | 34−13.5%88.0% | 43−16.9%90.3% | 36+28.7%88.7% | 37−22.3%94.1% | 39−35.7%93.6% | 51−34.0%94.5% | 28—85.6% | 47—91.0% | 61—92.6% | 78—95.0% | |
| Property, plant and equipment | 0.2—0.4% | 0.2−25.8%0.4% | 0.2−43.8%0.5% | 0.2−64.4%0.5% | 0.2−64.5%0.4% | 0.2−65.4%0.6% | 0.3−55.6%0.8% | 0.5−42.7%1.3% | 0.6−44.0%1.1% | 0.7—2.0% | 0.7—1.4% | 0.9—1.4% | 1.1—1.3% | |
| Right-of-use (leased) assets | 0.3—0.8% | 0.3−50.6%0.8% | 0.4−44.3%1.1% | 0.5−39.4%1.2% | 0.5−35.4%1.1% | 0.6−32.5%1.5% | 0.7−31.3%1.8% | 0.8−29.4%1.8% | 0.8−27.8%1.5% | 0.9—2.8% | 1.0—1.9% | 1.1—1.6% | 1.2—1.4% | |
| Total assets | 40—100% | 40−2.5%100% | 36−7.9%100% | 39−8.0%100% | 47−12.9%100% | 41+24.2%100% | 39−24.8%100% | 42−36.4%100% | 54−33.7%100% | 33—100% | 52—100% | 66—100% | 82—100% | |
| Accounts payable | 1.3—3.2% | 1.3−18.8%3.2% | 1.6−30.9%4.5% | 2.2+52.0%5.7% | 2.1+9.3%4.4% | 1.6+64.1%3.9% | 2.3+102%5.9% | 1.4−42.9%3.4% | 1.9−23.1%3.5% | 1.0—2.9% | 1.2—2.2% | 2.5—3.8% | 2.5—3.0% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 12—30.5% | 13—32.4% | 13—30.4% | 13—23.9% | — | — | — | 0—0.0% | |
| Current liabilities | 22—55.0% | 22−24.1%55.0% | 22−23.2%62.3% | 16−44.8%41.8% | 16−43.3%34.9% | 29+37.5%70.7% | 29+45.7%74.7% | 29+51.8%69.7% | 29+70.4%53.6% | 21—63.9% | 20—38.6% | 19—29.2% | 17—20.9% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0.1−85.3%0.2% | 0.2−69.6%0.4% | 0.2−58.5%0.5% | 0.3−50.4%0.8% | 0.4−44.1%1.1% | 0.5−39.4%1.2% | 0.6−35.9%1.1% | 0.7—2.0% | 0.7—1.4% | 0.8—1.2% | 0.9—1.1% | |
| Total liabilities | 46—115% | 46−20.9%115% | 32−44.0%88.0% | 23−62.6%58.6% | 22−65.0%47.5% | 58−13.5%142% | 57−13.4%145% | 61−6.2%144% | 64+3.5%118% | 67—203% | 65—126% | 65—97.7% | 62—75.8% | |
| Retained earnings | −360—−904% | −360—−904% | −348—−966% | −335—−863% | −325—−689% | −317—−775% | −317—−809% | −317—−751% | −307—−567% | −291—−883% | −268—−515% | −251—−378% | −230—−282% | |
| Shareholders' equity | −6.0—−15.0% | −6.0—−15.0% | 4.3—12.0% | 16—41.4% | 25—52.5% | −17—−41.7% | −17—−44.7% | −19−1332%−44.0% | −9.9−150%−18.2% | −34—−103% | −13—−25.6% | 1.5—2.3% | 20—24.2% | |
| Total liabilities and equity | 40—100% | 40−2.5%100% | 36−7.9%100% | 39−8.0%100% | 47−12.9%100% | 41+24.2%100% | 39−24.8%100% | 42−36.4%100% | 54−33.7%100% | 33—100% | 52—100% | 66—100% | 82—100% | |
| Shares outstanding | 17—— | 17+81.0%— | 17+85.6%— | 17−81.3%— | 17+87.2%— | 9.5−79.2%— | 9.3−78.2%— | 92+116%— | 9.2r92−78.4%— | 46—— | 42—— | 42—— | 42—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 4.7+38.8%20.5% | 1.9+166%27.6% | 1.2+36.6%20.7% | 0.9−12.6%17.9% | 0.7*−9.3%13.5% | 0.7−65.9%5.0% | 0.9−60.1%7.0% | 1.0−50.5%29.8% | 0.8*−63.6%220% | 2.1—— | 2.2—43.0% | 2.1—54.2% | 2.1*—104% | |
| Cash from operating activities | −32—−140% | −9.0*−193%−131% | −9.3*—−158% | −9.2—−182% | −4.6*—−90.2% | 9.7*—67.5% | −10*—−79.1% | −13—−369% | −16*—−4670% | −8.6*—— | −16*—−316% | −20—−521% | −15*—−730% | |
| Capital expenditure | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | −0.0*—— | −0.0*—−0.2% | 0—0.0% | −0.2*—−11.4% | |
| Cash from investing activities | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*−100%0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0.0*—2.3% | −0.0*—— | −0.0*—−0.2% | 0—0.0% | −0.2*—−11.4% | |
| Cash from financing activities | 26−5.9%112% | 12*—177% | −0.1*—−2.1% | −0.1—−2.4% | 14*−65.4%268% | −4.0*—−27.8% | −4.2*—−32.7% | −4.1—−118% | 39*—11461% | −0.4*—— | −0.6*—−12.4% | −0.7—−17.3% | −0.0*—−1.4% | |
| Change in cash | −6.4—−28.1% | 3.2*−43.9%46.2% | −9.4*—−160% | −9.3—−185% | 9.1*−61.3%178% | 5.7*—39.7% | −14*—−112% | −17—−487% | 23*—6794% | −9.0*—— | −17*—−329% | −21—−539% | −15*—−743% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Verrica Pharmaceuticals Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- License and collaboration revenue$20 M57%+1949%
- Product revenue, net(total)$15 M43%+133%
- License and Collaboration Revenue, Commercial Supply and Development$2 M6.5%+130%
Business segments
- Operating$36 M100%+370%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Verrica Pharmaceuticals Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Jayson Rieger | $741 K | $437 K | $906 K | $30 |
| 2024Ted White, Jayson Rieger | $2.6 M | −$468 K | $1.2 M | $25 |
| 2023Ted White | $3.5 M | $4.6 M | $2.3 M | $266 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Verrica Pharmaceuticals Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Restructuring 1 · Directors and officers 10 · Material agreement 5 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2025 | $50 M | Private placement after listing | $50 to $250 million | 21 | equity, options | SEC |
| Feb 2018 | $20 M | No. 3 | $10 to $50 million | 2 | equity | SEC |
| Dec 2017 | $5 M | No. 2 | $2 to $10 million | 1 | equity | SEC |
| Dec 2015 | $2 M | No. 1 | $2 to $10 million | 14 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
FDA drug approvals: Verrica Pharmaceuticals Inc.#
1 approved applications held; 1 approvals and 0 new uses in 2023.
| Approved | Drug | Kind |
|---|---|---|
| 2023-07-21 | YcanthCantharidin · NDA212905 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (VERRICA PHARMS), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | 47 | · | · | 47 |
| 2022 | · | · | · | · | 20 | · | · | · | · | · | · | · | 20 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 47 people | Restructuring planSEC 8-K | “(the “Company”) announced a reduction of its workforce by 47 employees, which the Company expects to be substantially completed by October 1, 2024.” | Filing | |
| 20 people | Restructuring planSEC 8-K | “(the “Company”), in order to streamline operations and reduce costs, approved a plan to reduce its workforce by terminating 20 employees, which the Company expects to be completed …” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Verrica Pharmaceuticals Inc. compares in Biotechnology
- Market cap$76 M · higher than 32% of 726
- Revenue$36 M · higher than 56% of 647
- Net margin-102.8% · higher than 41% of 408
- Revenue growth370.0% · higher than 93% of 438
- Price / sales2.5× · lower than 81% of 339
- Price / book3.1× · lower than 48% of 534
- FCF yield-23.1% · higher than 41% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Verrica Pharmaceuticals Inc.🇺🇸 | $76 M | — | -102.8% | +370.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Sep 21, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Verrica Pharmaceuticals Inc.? Verify and update this profile — free
Show Verrica Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.